Cue Biopharma (CUE) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed Cue Biopharma (CUE) over the past year, losing 7.6% versus a loss of 13.2%. Over five years, CUE leads with a -94.1% price change compared with -98.2% for YARW. Yarrow Bioscience is the larger company by market cap ($184.9 million vs $162.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | YARW |
|---|---|---|
| Share price | $22.33 | $19.87 |
| Market cap | $162.21M | $184.88M |
| 1-day change | -0.80% | +5.83% |
| YTD return | +144.04% | -31.48% |
| 1-year return | -13.25% | -7.58% |
| 5-year return | -94.09% | -98.19% |
| EPS (TTM) | $-29.59 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $46.95 |
| 52-week low | $4.98 | $16.05 |
| Distance from 52-week high | -50.92% | -57.68% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +294.09% | +186.86% |
| Average volume | 267.15K | 88.98K |
| Shares outstanding | 7.26M | 9.30M |
| Employees | 29 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
CUE vs YARW FAQ
Which is bigger, Cue Biopharma or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $184.88M compared with $162.21M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or YARW?
YARW returned -7.58% over the past 12 months, compared with -13.25% for CUE (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.